Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GRM5 | P41594 | 15/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099675 | 0.77 | RAB9A (0.55) | MEN1KMT2AGRM5 | |
| SCHEMBL16100329 | 0.77 | KMT2A (0.52) | MEN1KMT2AGRM5 | |
| SCHEMBL21756473 | 0.75 | ALDH1A1 (0.46) | KMT2AGRM5 | |
| SCHEMBL21753809 | 0.75 | SMN1; SMN2 (0.45) | MEN1KMT2AGRM5 | |
| SCHEMBL21753816 | 0.74 | SIGMAR1 (0.53) | MEN1KMT2AGRM5 | |
| SCHEMBL21753810 | 0.73 | ATM (0.47) | MEN1KMT2AGRM5 | |
| SCHEMBL21753815 | 0.73 | GRM5 (0.49) | MEN1KMT2AGRM5 | |
| SCHEMBL21753822 | 0.73 | SMN1; SMN2 (0.54) | MEN1KMT2A | |
| SCHEMBL21753827 | 0.73 | SMN1; SMN2 (0.42) | MEN1KMT2AGRM5 | |
| SCHEMBL21753824 | 0.73 | GRM5 (0.50) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | claimed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | MEN1 687/4885KMT2A 2542/4885GRM5 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.